Tinsley SM, Grande C, Olson K, Plato L, Jacobs I. Potential of biosimilars to increase access to biologics: considerations for advanced practice providers in oncology. J Adv Pract Oncol. 2018;9(7):699. https://doi.org/10.6004/jadpro.2018.9.7.2.

Article  PubMed  PubMed Central  Google Scholar 

Antman EM, Creager MA, Houser SR, Warner JJ, Konig M. American Heart Association principles on the accessibility and affordability of drugs and biologics: a presidential advisory from the American Heart Association. Circulation. 2017;136(24):e441–7. https://doi.org/10.1161/CIR.0000000000000551.

Article  PubMed  Google Scholar 

Kirchhoff CF, Wang XZM, Conlon HD, Anderson S, Ryan AM, Bose A. Biosimilars: key regulatory considerations and similarity assessment tools. Biotechnol Bioeng. 2017;114(12):2696–705. https://doi.org/10.1002/bit.26438.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Safdar A, Butt MH, Ahmad A, Zaman M. Progress in oncology biosimilars till 2020: scrutinizing comparative studies of biosimilar monoclonal antibodies. J Oncol Pharm Pract. 2021;27(5):1195–204. https://doi.org/10.1177/10781552211016083.

Article  PubMed  Google Scholar 

Triantafyllidi E, Triantafillidis JK. Systematic review on the use of biosimilars of trastuzumab in HER2+ breast cancer. Biomedicines. 2022;10(8):2045. https://doi.org/10.3390/biomedicines10082045.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stebbing J, Baranau YV, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, et al. Double-blind, randomized phase III study to compare the efficacy and safety of CT-P6, trastuzumab biosimilar candidate versus trastuzumab as neoadjuvant treatment in HER2 positive early breast cancer (EBC). J Clin Oncol. 2017. https://doi.org/10.1200/JCO.2017.35.15_suppl.510.

Article  Google Scholar 

Lyman GH, Balaban E, Diaz M, Ferris A, Tsao A, Voest E, et al. American Society of Clinical Oncology statement: biosimilars in oncology. J Clin Oncol. 2018;36(12):1260–5. https://doi.org/10.1200/jco.2017.77.4893.

Article  PubMed  Google Scholar 

Chen B, Nagai S, Armitage JO, Witherspoon B, Nabhan C, Godwin AC, et al. Regulatory and clinical experiences with biosimilar filgrastim in the U.S., the European Union, Japan, and Canada. Oncologist. 2019;24(4):537–48. https://doi.org/10.1634/theoncologist.2018-0341.

Article  PubMed  PubMed Central  Google Scholar 

Jensen TB, Kim SC, Jimenez-Solem E, Bartels D, Christensen HR, Andersen JT. Shift from adalimumab originator to biosimilars in Denmark. JAMA Intern Med. 2020;180(6):902–3. https://doi.org/10.1001/jamainternmed.2020.0338.

Article  PubMed  PubMed Central  Google Scholar 

Mouslim MC, Trujillo AJ, Alexander GC, Segal JB. Association between filgrastim biosimilar availability and changes in claim payments and patient out-of-pocket costs for biologic filgrastim products. Value Health. 2020;23(12):1599–605. https://doi.org/10.1016/j.jval.2020.06.014.

Article  PubMed  PubMed Central  Google Scholar 

Lobo F, Río-Álvarez I. Barriers to biosimilar prescribing incentives in the context of clinical governance in Spain. Pharmaceuticals (Basel). 2021;14(3):283. https://doi.org/10.3390/ph14030283.

Article  PubMed  Google Scholar 

Moorkens E, Godman B, Huys I, Hoxha I, Malaj A, Keuerleber S, et al. The expiry of Humira® market exclusivity and the entry of adalimumab biosimilars in Europe: an overview of pricing and national policy measures. Front Pharmacol. 2020;11: 591134. https://doi.org/10.3389/fphar.2020.591134.

Article  CAS  PubMed  Google Scholar 

Okoro RN. Biosimilar medicines uptake: the role of the clinical pharmacist. Explor Res Clin Soc Pharm. 2021;1: 100008. https://doi.org/10.1016/j.rcsop.2021.100008.

Article  PubMed  PubMed Central  Google Scholar 

Druedahl LC, Almarsdóttir AB, KälvemarkSporrong S, De Bruin ML, Hoogland H, Minssen T, et al. A qualitative study of biosimilar manufacturer and regulator perceptions on intellectual property and abbreviated approval pathways. Nat Biotechnol. 2020;38(11):1253–6. https://doi.org/10.1038/s41587-020-0717-7.

Article  CAS  PubMed  Google Scholar 

Druedahl LC, KälvemarkSporrong S, van de Weert M, De Bruin MLM, Hoogland H, Minssen T, et al. Evolving biosimilar clinical requirements: a qualitative interview study with industry experts and European national medicines agency regulators. BioDrugs. 2021;35:351–61. https://doi.org/10.1007/s40259-021-00478-7.

Article  PubMed  Google Scholar 

Baumgart DC, Misery L, Naeyaert S, Taylor PC. Biological therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities? Front Pharmacol. 2019;10:279. https://doi.org/10.3389/fphar.2019.00279.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73(1):198–206. https://doi.org/10.1136/annrheumdis-2012-202603.

Article  CAS  PubMed  Google Scholar 

Gershon N, Berchenko Y, Hall PS, Goldstein DA. Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer. Cost Effect Resour. 2019;17(1):1–10. https://doi.org/10.1186/s12962-019-0174-7.

Article  Google Scholar 

Al-Ziftawi NH, Shafie AA, Mohamed Ibrahim MI. Cost-effectiveness analyses of breast cancer medications use in developing countries: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):655–66. https://doi.org/10.1080/14737167.2020.1794826.

Article  PubMed  Google Scholar 

Tubic B, Marković-Peković V, Jungić S, Allocati E, Godman B. Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: findings and implications. Med Access Point Care. 2021;5: 23992026211027692. https://doi.org/10.1177/23992026211027692.

Article  PubMed  PubMed Central  Google Scholar 

Peyrin-Biroulet L, Lonnfors S, Avedano L, Danese S. Changes in inflammatory bowel disease patients’ perspectives on biosimilars: a follow-up survey. United Eur Gastroenterol. 2019;7(10):1345–52. https://doi.org/10.1177/2050640619883704.

Article  Google Scholar 

Pineles D, Arsuaga A, Malter LB, Bosworth BP, Hudesman DP, Chang S. Patient perceptions regarding the use of biosimilars in inflammatory bowel disease. Am J Gastroenterol. 2017;112:S418–9. https://doi.org/10.14309/00000434-201710001-00750.

Article  Google Scholar 

Fenwick S, Thakur K, Munro D. Nurse and patient perceptions and preferences for subcutaneous autoinjectors for inflammatory joint or bowel disease: findings from a European survey. Rheumatol Ther. 2019;6(2):195–206. https://doi.org/10.1007/s40744-019-0144-8.

Article  PubMed  PubMed Central  Google Scholar 

Sullivan E, Piercy J, Waller J, Black CM, Kachroo S. Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn’s disease across Germany. PLoS One. 2017;12(4): e0175826. https://doi.org/10.1371/journal.pone.0175826.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Smastuen MC, Brandvold M, Andenaes R. Is patients’ satisfaction with being switched to a biosimilar medication associated with their level of health literacy? Results from a Norwegian user survey. Ann Rheum Dis. 2018;77:86. https://doi.org/10.1136/annrheumdis-2018-eular.5993.

Article  Google Scholar 

Young D, Cummings F, Latter S. Patient perspectives of successful adalimumab biosimilar transitioning in Crohn’s disease: an interview study. Eur J Hosp Pharm. 2022. https://doi.org/10.1136/ejhpharm-2022-003371.

Article  PubMed  Google Scholar 

Scherlinger M, Langlois E, Germain V, Schaeverbeke T. Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4). Semin Arthritis Rheum. 2019;48(5):927–32. https://doi.org/10.1016/j.semarthrit.2018.07.005.

Article  PubMed  Google Scholar 

Gasteiger C, Scholz U, Petrie KJ, Dalbeth N. A bio-what? Medical companions’ perceptions towards biosimilars and information needs in rheumatology. Rheumatol Int. 2022;42(11):1993–2002. https://doi.org/10.1007/s00296-021-05037-5.

Article  PubMed  Google Scholar 

Frantzen L, Cohen J-D, Trope S, Beck M, Munos A, Sittler M-A, et al. Patients’ information and perspectives on biosimilars in rheumatology: a French nation-wide survey. Joint Bone Spine. 2019;86(4):491–6. https://doi.org/10.1016/j.jbspin.2019.01.001.

Article  PubMed  Google Scholar 

Kovitwanichkanont T, Raghunath S, Wang D, Kyi L, Pignataro S, Morton S, et al. Who is afraid of biosimilars? Openness to biosimilars in an Australian cohort of patients with rheumatoid arthritis. Intern Med J. 2020;50(3):374–7. https://doi.org/10.1111/imj.14753.

Article  PubMed  Google Scholar 

Wu Q, Lian Z, Wang X, Cheng H, Sun J, Yu H, et al. Factors associated with the uptake of biosimilars for breast cancer treatment from the perspectives of physicians and patients: evidence from China. Front Pharmacol. 2023. https://doi.org/10.3389/fphar.2022.1044798.

Article  PubMed  PubMed Central  Google Scholar 

Teeple A, Ginsburg S, Howard L, Huff L, Reynolds C, Walls D, et al. Patient attitudes about non-medical switching to biosimilars: results from an online patient survey in the United States. Curr Med Res Opin. 2019;35(4):603–9. https://doi.org/10.1080/03007995.2018.1560221.

Article  CAS  PubMed  Google Scholar 

Waller J, Sullivan E, Piercy J, Black CM, Kachroo S. Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany. Patient Prefer Adher. 2017;11:519–30. https://doi.org/10.2147/ppa.S129333.

Article  Google Scholar 

Mohd Sani N, Aziz Z, Panickar R, Kamarulzaman A. Pharmacists’ perspectives of biosimilars: a systematic review. BioDrugs. 2022;36(4):489–508. https://doi.org/10.1007/s40259-022-00541-x.